The Business Times
MIND THE GAP
·
SUBSCRIBERS

Integrated Shield riders: Fresh focus on cancer drug cover, brace for premium hikes

IP riders now have additional cancer drug benefits far more than the base plans, raising the question of whether current premiums are sustainable

Genevieve Cua

Genevieve Cua

Published Mon, Apr 17, 2023 · 06:00 AM
    • Escalating costs of cancer drugs prompted the creation of a cancer drug list by the health ministry last year, in efforts to rein in costs. Private insurers under the Integrated Shield scheme have to comply with the list this year.
    • Escalating costs of cancer drugs prompted the creation of a cancer drug list by the health ministry last year, in efforts to rein in costs. Private insurers under the Integrated Shield scheme have to comply with the list this year. The Straits Times

    RIDERS to supplement private Integrated Shield Plans (IPs) are set to take on new significance for policyholders, particularly if you are concerned about the extent of cancer drug coverage.

    The big question is – are today’s rider premiums sustainable given the riders’ enlarged role in outpatient cancer cover?

    Insurers in the IP scheme recently rolled out their base IP plans and riders, with reference to the caps for cancer drug coverage, in line with the cancer drug list (CDL) issued by the health ministry last year.

    Mind the GapSpotlight

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback
    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More